EpiBiologics website screenshot

EpiBiologics

EpiBiologics is a clinical-stage biotechnology company based in San Mateo, California, developing bispecific antibodies for directed extracellular protein degradation. Its proprietary EpiTAC platform leverages an atlas of 270+ degradation-inducing cell-surface receptors to build tissue-selective therapies that degrade disease-causing proteins while sparing healthy tissue, targeting cancer, autoimmune, and other serious diseases. The company dosed its first patient with EPI-326 (an EGFR-driven solid-tumor bispecific) in a Phase 1 study in April 2026 and closed a $107M Series B round in January 2026. Backed by GV, EpiBiologics was added to the API Evangelist network as a portfolio-lead profile; it publishes a corporate website but no public developer/API surface.

EpiBiologics is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Therapeutics, and Drug Discovery.

EpiBiologics’ developer surface includes support and 3 more developer resources.

🌐 Visit website 📡 Source on GitHub
8.4/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyLife SciencesBiotechnologyTherapeuticsDrug DiscoveryProtein DegradationAntibodiesOncology

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 8.4/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.9 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/epibiologics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Epibiologics Domain Security

TLSv1.3 · HSTS

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support
Support

Company 2

The organization behind the API

Website
Website
 About
About

Source (apis.yml)

apis.yml Raw ↑ 
aid: epibiologics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/epibiologics.png
name: EpiBiologics
description: EpiBiologics is a clinical-stage biotechnology company based in San Mateo, California, developing bispecific
  antibodies for directed extracellular protein degradation. Its proprietary EpiTAC platform leverages an atlas of 270+ degradation-inducing
  cell-surface receptors to build tissue-selective therapies that degrade disease-causing proteins while sparing healthy tissue,
  targeting cancer, autoimmune, and other serious diseases. The company dosed its first patient with EPI-326 (an EGFR-driven
  solid-tumor bispecific) in a Phase 1 study in April 2026 and closed a $107M Series B round in January 2026. Backed by GV,
  EpiBiologics was added to the API Evangelist network as a portfolio-lead profile; it publishes a corporate website but no
  public developer/API surface.
url: https://raw.githubusercontent.com/api-evangelist/epibiologics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Life Sciences
- Biotechnology
- Therapeutics
- Drug Discovery
- Protein Degradation
- Antibodies
- Oncology
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://www.epibiologics.com
- type: About
  url: https://www.epibiologics.com/about-us
- type: Support
  url: https://www.epibiologics.com/contact
- type: DomainSecurity
  url: security/epibiologics-domain-security.yml
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence